10955 VISTA SORRENTO PARKWAY, SAN DIEGO, CA
Reports First Quarter 2026 Financial Results and Business Highlights
Director Reclassification - Eric Dobmeier Moves from Class III to Class II
Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Announces Collaboration and Exclusive Worldwide License Agreement to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors
Reports Third Quarter 2025 Financial Results and Business Highlights
Changes in Board, Management or Compensation
Reports Second Quarter 2025 Financial Results and Business Highlights
Shareholder votes
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities